May 2004
Volume 45, Issue 13
ARVO Annual Meeting Abstract  |   May 2004
Effects of Systemic COX–2 Inhibitor Therapy on Intraocular Pressure
Author Affiliations & Notes
  • H.P. Wadia
    Ophthalmology, West Virginia University, Morgantown, WV
  • T. Realini
    Ophthalmology, West Virginia University, Morgantown, WV
  • Footnotes
    Commercial Relationships  H.P. Wadia, None; T. Realini, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 4474. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H.P. Wadia, T. Realini; Effects of Systemic COX–2 Inhibitor Therapy on Intraocular Pressure . Invest. Ophthalmol. Vis. Sci. 2004;45(13):4474.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: Prostaglandins are potent IOP reducers. Production of endogenous prostaglandins from arachidonic acid requires the cyclo–oxygenase–2 (COX–2) enzyme. Inhibitors of this enzyme are widely used to manage systemic inflammatory conditions. This study was carried out to determine if systemic COX–2 inhibitor therapy raises IOP (theoretically by reducing endogenous production of IOP–lowering prostaglandins). Methods: 25 patients on systemic COX–2 therapy were identified from consecutive patients presenting for routine eye examinations. These were matched for age (within 5 years), sex and race to 25 similarly–identified patients receiving no COX–2 therapy. All patients in both groups were free of glaucoma, ocular hypertension, or other conditions known to affect IOP, and none were on topical or systemic medications (beta blockers, corticosteroids, etc) known to affect IOP (other than COX–2 inhibitors). Mean IOP of the two groups were compared. Results: In both groups, 17/25 patients were female and all were Caucasian. Mean IOP in the COX–2 treated group was 16.4 +/– 2.4 mmHg, compared with a mean IOP of 14.0 +/– .6 mmHg in the group not on COX–2 therapy (two–tailed t–test p=0.00019). Conclusions: Patients receiving systemic COX–2 inhibitor therapy have higher IOP than age–, sex– and race–matched controls. A possible explanation is that COX–2 inhibition reduces the endogenous production of prostaglandins, which are known to lower IOP.

Keywords: intraocular pressure • drug toxicity/drug effects 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.